Carfilzomib-induced thrombotic microangiopathy is underestimated in clinical practice: A report of five patients and literature review-Reference-Cited by-同舟云学术

Carfilzomib-induced thrombotic microangiopathy is underestimated in clinical practice: A report of five patients and literature review

Published:2022-04-03 Issue:5 Volume:63 Page:1102-1110
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Terao Toshiki¹^ORCID,Tsushima Takafumi¹,Miura Daisuke¹,Ikeda Daisuke¹,Fukumoto Ami¹,Kuzume Ayumi¹,Tabata Rikako¹,Narita Kentaro¹^ORCID,Takeuchi Masami¹,Matsue Kosei¹^ORCID

Affiliation:

1. Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Japan

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2022.2057485

Reference33 articles.

1. Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

2. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

3. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study

4. Syndromes of Thrombotic Microangiopathy

5. Proteasome inhibitor‐associated thrombotic microangiopathy: A review of cases reported to the FDA adverse event reporting system and published in the literature

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Carfilzomib-induced thrombotic microangiopathy (TMA) refractory to eculizumab: A case report and literature review;Annals of Hematology;2024-08-27

2. Carfilzomib-associated thrombotic microangiopathy: clinical features and outcomes;Nephrology Dialysis Transplantation;2024-04-24

3. Side Effects of Treatment in Multiple Myeloma;Side Effects of Cancer Therapy;2023-10-26

4. Complement biology for hematologists;American Journal of Hematology;2023-03-31

5. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis;Journal of the American College of Cardiology;2023-03